JoVE Logo
Faculty Resource Center

Sign In

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

DOI :

10.3791/58237-v

June 14th, 2018

June 14th, 2018

11,830 Views

1Center for Childhood Cancer and Blood Disease, Nationwide Children's Hospital, 2Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, 3Center for Clinical and Translational Research, Nationwide Children's Hospital Research Institute

Here, we present a protocol to genetically modify primary or expanded human natural killer (NK) cells using Cas9 Ribonucleoproteins (Cas9/RNPs). By using this protocol, we generated human NK cells deficient for transforming growth factor–b receptor 2 (TGFBR2) and hypoxanthine phosphoribosyltransferase 1 (HPRT1).

-- Views

Related Videos

article

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

article

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

article

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

article

Whole-Mount Fluorescence In Situ Hybridization to Study Spermatogenesis in the Anopheles Mosquito

article

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

article

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

article

Author Spotlight: Neutrophil Extracellular Traps Imaging in Human and Mouse Tissues

article

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface

article

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

article

Author Spotlight: Studying Macrophage-Epithelial Cell Interactions in Salivary Gland Regeneration After Injury

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved